MRK - Merck & Co., Inc.
89.57 0.00 (0.00%)
After hours: 4:53PM EST
| Previous close | 88.98 |
| Open | 89.04 |
| Bid | 89.55 x 1100 |
| Ask | 89.64 x 1400 |
| Day's range | 88.91 - 89.96 |
| 52-week range | 70.89 - 89.96 |
| Volume | 6118008 |
| Avg. volume | 8,099,048 |
| Market cap | 228B |
| Beta (5Y Monthly) | 0.53 |
| PE ratio (TTM) | 25.03 |
| EPS (TTM) | 3.58 |
| Earnings date | 5 Feb 2020 |
| Forward dividend & yield | 2.44 (2.74%) |
| Ex-dividend date | 2019-12-13 |
| 1y target est | 97.56 |
- Zacks
Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor
Lilly (LLY) initiates a phase III study on its oral RET inhibitor, selpercatinib, in treatment-naive, RET fusion-positive NSCLC patients.
- Investing.com
NewsBreak: Stocks Shoot Higher on Trade Deal Report
Investing.com – Stocks pushed higher Thursday afternoon on reports the United States and China have mostly agreed on a phase one trade deal.
- Zacks
AstraZeneca's Imfinzi Gets China Nod for Stage III NSCLC
AstraZeneca's (AZN) Imfinzi becomes the first immunotherapy to receive approval in China for treating unresectable, stage III NSCLC, which has not progressed following chemotherapy and radiation therapy.
- Business Wire
Data from Exploratory Analysis Show Merck’s KEYTRUDA® (pembrolizumab) Improved Overall Survival as Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Regardless of KRAS Mutational Status
Data from Exploratory Analysis Show KEYTRUDA Improved Overall Survival as Monotherapy for the First-Line Treatment of NSCLC Regardless of KRAS
- Zacks
Sanofi, Regeneron to Amend Agreement for Kevzara & Praulent
Sanofi (SNY) intends to amend its antibody collaboration with Regeneron related to Kevzara and Praulent into a royalty-based agreement. Agreement terms for Dupixent to remain intact.
- Zacks
Roche's (RHHBY) sBLA for Asthma Drug Xolair Accepted by FDA
The FDA accepts Roche's (RHHBY) allergic asthma drug Xolair's sBLA for the treatment of nasal polyps in adult patients aged 18 years or above with inadequate response to intranasal corticosteroids.
- Zacks
Sanofi (SNY) Looks Good: Stock Adds 6.2% in Session
Sanofi (SNY) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Zacks
Why Biotech ETFs are Surging to New Highs
increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
- Zacks
Biotech ETFs Hit New Highs on Deal Activities
Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
- Zacks
Merck to Buy ArQule for $2.7B to Boost Cancer Portfolio
Merck (MRK) offers to acquire ArQule for a deal value of $2.7 billion. The transaction will add ArQule's lead investigational candidate ARQ 531 to Merck's oncology portfolio.
- Zacks
Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms
Merck offers to buy ArQule for $2.7 billion while Sanofi signs a definitive deal to purchase Synthorx for $2.5 billion.
- Zacks
Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More
Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).
- Zacks
Bristol-Myers' (BMY) Lymphoma Drug Meets Goals in Key Study
Bristol-Myers' (BMY) TRANSCEND NHL 001 study on CAR T-cell therapy drug meets endpoints.
- Investing.com
Stocks - Canopy Growth, ArQule Rise in Premarket; Microsoft Edges Lower
Investing.com -- Stocks in focus in premarket trade on Monday, 9th December.
- Zacks
Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar
FDA gives nod to Amgen's (AMGN) Avsola (ABP 710), a biosimilar of J&J's blockbuster rheumatoid arthritis drug, Remicade.
- Zacks
Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ
The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.
- Zacks
AstraZeneca's Lynparza Gets China Nod in First-Line Setting
AstraZeneca's (AZN) Lynparza receives approval in China for first-line maintenance treatment of advanced ovarian cancer with BRCA-mutation.
- Zacks
Bristol-Myers' Orencia Gets Breakthrough Therapy Tag for GvHD
The FDA grants Breakthrough Therapy designation to Bristol-Myers Squibb's (BMY) Orencia for the prevention of moderate-to-severe acute GvHD in hematopoietic SCT from unrelated donors.
- Zacks
J&J Stock Witnesses Volatility in '19: What to Expect in 2020
Here we discuss the ups and downs of J&J's (JNJ) stock this year.
- Reuters
AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or death by 70% when compared to placebo. Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, the companies said.
- Zacks
Bristol-Myers' Reblozyl to be Reviewed by FDA Committee
Bristol-Myers (BMY) and Acceleron Pharma Inc.'s sBLA for Reblozyl in patients with myelodysplastic syndromes will be reviewed by the FDA's Oncologic Drugs Advisory Committee.
- Zacks
Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
- Zacks
Roche's Tecentriq-Chemo Combo Gets FDA Nod in First-Line NSCLC
Roche (RHHBY) obtains FDA approval for Tecentriq in combination with chemotherapy for the first-line treatment of adults with metastatic NSCLC.
- Zacks
Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer (Revised)
Pfizer (PFE)/Astellas' Xtandi gets approval in China to treat metastatic castration-resistant prostate cancer (CRPC).
